The main focus of the research group is in translational research in gynaecological cancers. In particular biomarker discovery and development (specifically immunological markers) in ovarian and endometrial cancers. The biomarkers are now in the process of being tested for diagnosis and surgical prognosis. The concept of predicting surgical outcome in ovarian cancer is a step in developing personalised medicine and providing patients with best care possible.
Recent advances in oncolgy have improved survival in patients with cancer but research into surgery may have additional benefits for the patient. Clinical research into optimal treatment of cervival preinvasive lesions has been a focus. We have shown that clear margins of resection has a significant effect on reducing risk of recurrence from preinvasive disease.
et al., 2020, Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression, Journal for Immunotherapy of Cancer, ISSN:2051-1426
et al., 2020, The application of metabolomics in ovarian cancer management: a systematic review., Int J Gynecol Cancer
Phelps DL, Saso S, Ghaem-Maghami S, 2020, Is ovarian cancer surgery stuck in the dark ages?: a commentary piece reviewing surgical technologies, British Journal of Cancer, ISSN:0007-0920
Phelps DL, Saso S, Ghaem-Maghami S, 2020, Analysis of worldwide surgical outcomes in COVID-19-infected patients: a gynecological oncology perspective, Future Science Oa, ISSN:2056-5623, Pages:FS0629-FS0629
et al., 2020, The intelligent knife (iKnife) and its intraoperative diagnostic advantage for the treatment of cervical disease (vol 117, pg 7338, 2020), Proceedings of the National Academy of Sciences of the United States of America, Vol:117, ISSN:0027-8424, Pages:18892-18892